Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Dec;18(6):837–847. doi: 10.1111/j.1365-2125.1984.tb02553.x

Nicardipine: pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers.

C Thuillez, M Gueret, P Duhaze, F Lhoste, J R Kiechel, J F Giudicelli
PMCID: PMC1463674  PMID: 6397218

Abstract

The effects of nicardipine, 20 mg, three times daily, nicardipine slow release, 30 mg, twice daily and a placebo on brachial and carotid arteries diameters and flows have been investigated by the pulsed Doppler technique during a single blind and cross-over study performed in six healthy volunteers. Simultaneously, nicardipine plasma levels and relative bioavailability were determined. Nicardipine significantly increased brachial and carotid arteries diameters (by 16 and 10% respectively) and flows (by 60 and 35% respectively). These effects peaked after 4 h and lasted no longer than 6 h. Forearm vascular resistance was significantly decreased. Hence nicardipine dilated both large and small arteries. Nicardipine slow release elicited the same effects on brachial and carotid arteries diameters and flows as nicardipine. These effects peaked at 6 h and lasted up to 10 h. Although the profiles of the pharmacodynamic effects and of the kinetics of nicardipine were almost parallel in each individual after administration of both nicardipine formulations, there was no correlation between the nicardipine plasma relative bioavailability and its effects on brachial and carotid arteries blood flows when considering all subjects together.

Full text

PDF
837

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown M. J., Jenner D. A. Novel double-isotope technique for enzymatic assay of catecholamines, permitting high precision, sensitivity and plasma sample capacity. Clin Sci (Lond) 1981 Nov;61(5):591–598. doi: 10.1042/cs0610591. [DOI] [PubMed] [Google Scholar]
  2. Guazzi M., Olivari M. T., Polese A., Fiorentini C., Magrini F., Moruzzi P. Nifedipine, a new antihypertensive with rapid action. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):528–532. doi: 10.1002/cpt1977225part1528. [DOI] [PubMed] [Google Scholar]
  3. Higuchi S., Sasaki H., Sado T. Determination of a new cerebral vasodilator 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93) in plasma by electron capture gas chromatography. J Chromatogr. 1975 Jul 16;110(2):301–307. doi: 10.1016/0021-9673(75)85010-2. [DOI] [PubMed] [Google Scholar]
  4. Higuchi S., Sasaki H., Seki T. Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs and humans. Xenobiotica. 1980 Dec;10(12):897–903. doi: 10.3109/00498258009033823. [DOI] [PubMed] [Google Scholar]
  5. Hof R. P. Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem. Br J Pharmacol. 1983 Feb;78(2):375–394. doi: 10.1111/j.1476-5381.1983.tb09403.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Iliopoulou A., Turner P., Warrington S. J. Acute haemodynamic effects of a new calcium antagonist, nicardipine, in man. A comparison with nifedipine. Br J Clin Pharmacol. 1983 Jan;15(1):59–65. doi: 10.1111/j.1365-2125.1983.tb01464.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lederballe Pedersen O., Christensen N. J., Rämsch K. D. Comparison of acute effects of nifedipine in normotensive and hypertensive man. J Cardiovasc Pharmacol. 1980 Jul-Aug;2(4):357–366. doi: 10.1097/00005344-198007000-00003. [DOI] [PubMed] [Google Scholar]
  8. McAllister R. G., Jr Clinical pharmacology of slow channel blocking agents. Prog Cardiovasc Dis. 1982 Sep-Oct;25(2):83–102. doi: 10.1016/0033-0620(82)90022-6. [DOI] [PubMed] [Google Scholar]
  9. Pham-Huu-Trung M. T., Corvol P. A direct determination of plasma aldosterone. Steroids. 1974 Nov;24(5):587–508. doi: 10.1016/0039-128x(74)90013-0. [DOI] [PubMed] [Google Scholar]
  10. Safar M. E., Peronneau P. A., Levenson J. A., Toto-Moukouo J. A., Simon A. C. Pulsed Doppler: diameter, blood flow velocity and volumic flow of the brachial artery in sustained essential hypertension. Circulation. 1981 Feb;63(2):393–400. doi: 10.1161/01.cir.63.2.393. [DOI] [PubMed] [Google Scholar]
  11. Seki T., Takenaka T. Pharmacological evaluation of YC-93, a new vasodilator, in healthy volunteers. Int J Clin Pharmacol Biopharm. 1977 Jun;15(6):267–274. [PubMed] [Google Scholar]
  12. Takenaka T., Handa J. Cerebrovascular effects of YC-93, a new vasodilator, in dogs, monkeys and human patients. Int J Clin Pharmacol Biopharm. 1979 Jan;17(1):1–11. [PubMed] [Google Scholar]
  13. Takenaka T., Usuda S., Nomura T., Maeno H., Sado T. Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93). Arzneimittelforschung. 1976;26(12):2172–2178. [PubMed] [Google Scholar]
  14. Taylor S. H., Silke B., Ahuja R. C., Okoli R. Influence of nicardipine on the blood pressure at rest and on the pressor responses to cold, isometric exertion, and dynamic exercise in hypertensive patients. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):803–807. doi: 10.1097/00005344-198209000-00016. [DOI] [PubMed] [Google Scholar]
  15. Yamamoto M., Ohta T., Toda N. Mechanisms of relaxant action of nicardipine, a new Ca++-antagonist, on isolated dog cerebral and mesenteric arteries. Stroke. 1983 Mar-Apr;14(2):270–275. doi: 10.1161/01.str.14.2.270. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES